15 results match your criteria: "Centre de Référence National des Cytopénies Auto-immunes de l'Enfant (CEREVANCE)[Affiliation]"
Lupus
December 2024
Pediatric Department, Bordeaux University Hospital, Bordeaux, France.
Introduction: Systemic Lupus Erythematosus (SLE) can be diagnosed using the 2012 criteria of the Systemic Lupus International Collaborating Clinics (SLICC) and, more recently, the 2019 criteria of the European League Against Rheumatism/American College of Rheumatology (EULAR/ACR). Hematological involvement is scored differently by these classifications. Our objective was to compare both criteria in a cohort of children with autoimmune cytopenia (AIC)-associated SLE.
View Article and Find Full Text PDFAm J Hematol
July 2024
Centre de Référence National des Cytopénies Auto-immunes de l'Enfant (CEREVANCE), Bordeaux and Paris, France.
Refractory chronic immune thrombocytopenia (r-cITP) is one of the most challenging situations in chronic immune thrombocytopenia (cITP). Pediatric r-cITP is inconsistently defined in literature, contributing to the scarcity of data. Moreover, no evidence is available to guide the choice of treatment.
View Article and Find Full Text PDFBr J Haematol
October 2023
Division of Hematology, Childrens Hospital of ORange County (CHOC), University of California Irvine, Irvine, California, USA.
Since its first description by Evans in 1951, this syndrome has been linked to chronic immune thrombocytopenia with the concurrent or delayed onset of autoimmune haemolytic anaemia or neutropenia. For decades, the evolution of Evans syndrome (ES) has carried a poor prognosis and often resulted in chronic steroid exposure, multiple immune suppressing medications directed against T or B lymphocytes, and splenectomy. This paper presents a new view of ES based on recent advances in genomics which begin to classify patients based on their underlying molecular variants in previously described primary immune disorders.
View Article and Find Full Text PDFPediatric chronic immune thrombocytopenia (cITP) is a heterogeneous condition in terms of bleeding severity, second-line treatment use, association with clinical and/or biological immunopathological manifestations (IMs), and progression to systemic lupus erythematosus (SLE). No risk factors for these outcomes are known. Specifically, whether age at ITP diagnosis, sex, or IMs impact cITP outcomes is unknown.
View Article and Find Full Text PDFBlood
July 2022
Pediatric Hematology Unit, Robert-Debré University Hospital, AP-HP, Paris, France.
Splenectomy is effective in ∼70% to 80% of pediatric chronic immune thrombocytopenia (cITP) cases, and few data exist about it in autoimmune hemolytic anemia (AIHA) and Evans syndrome (ES). Because of the irreversibility of the procedure and the lack of predictions regarding long-term outcomes, the decision to undertake splenectomy is difficult in children. We report here factors associated with splenectomy outcomes from the OBS'CEREVANCE cohort, which prospectively includes French children with autoimmune cytopenia (AIC) since 2004.
View Article and Find Full Text PDFBr J Haematol
June 2022
Hematology Project Foundation, Affiliated to the Hematology Department of the San Bortolo Hospital, Vicenza, Italy.
Haematologica
February 2022
Centre de Référence National des Cytopénies Auto-immunes de l'Enfant (CEREVANCE), Bordeaux, France; Pediatric Oncology Hematology Unit, University Hospital, Plurithématique CIC (CICP), Centre d'Investigation Clinique (CIC) 1401, INSERM Bordeaux.
Pediatric-onset Evans syndrome (pES) is defined by both immune thrombocytopenic purpura (ITP) and autoimmune hemolytic anemia (AIHA) before the age of 18 years. There have been no comprehensive long-term studies of this rare disease, which can be associated to various immunopathological manifestations (IM). We report outcomes of the 151 patients with pES and more than 5 years of follow-up from the nationwide French prospective OBS'CEREVANCE cohort.
View Article and Find Full Text PDFNat Commun
October 2020
Université de Paris, Imagine institute, laboratory of Immunogenetics of Pediatric Autoimmune Diseases, INSERM UMR 1163, 24 boulevard du Montparnasse, 75015, Paris, France.
Autoimmunity can occur when a checkpoint of self-tolerance fails. The study of familial autoimmune diseases can reveal pathophysiological mechanisms involved in more common autoimmune diseases. Here, by whole-exome/genome sequencing we identify heterozygous, autosomal-dominant, germline loss-of-function mutations in the SOCS1 gene in ten patients from five unrelated families with early onset autoimmune manifestations.
View Article and Find Full Text PDFNeuropediatrics
August 2020
Service de Neurologie Pédiatrique, CHU de Bordeaux, Bordeaux, France.
Cutis laxa is a heterogeneous group of diseases, characterized by abundant and wrinkled skin and a variable degree of intellectual disability. Cutis laxa, autosomal recessive, type IIIA and autosomal dominant 3 syndromes are caused by autosomal recessive or de novo pathogenic variants in . Autosomal recessive variants are known to lead to the most severe neurological phenotype, and very few patients have been described.
View Article and Find Full Text PDFBr J Haematol
June 2020
Pediatric Hematology Unit, CIC1401, INSERM CICP, University Hospital of Bordeaux, Bordeaux, France.
Childhood chronic immune thrombocytopenic purpura (cITP) is a rare disease. In severe cases, there is no evidence for the optimal therapeutic strategy. Our aim was to describe the real-life management of non-selected children with cITP at diagnosis.
View Article and Find Full Text PDFBlood
July 2019
Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, Institut Imagine, Unité Mixte de Recherche (UMR) 1163, INSERM, Paris, France.
Evans syndrome (ES) is a rare severe autoimmune disorder characterized by the combination of autoimmune hemolytic anemia and immune thrombocytopenia. In most cases, the underlying cause is unknown. We sought to identify genetic defects in pediatric ES (pES), based on a hypothesis of strong genetic determinism.
View Article and Find Full Text PDFPediatr Blood Cancer
December 2017
Pediatric Hematology Unit, Centre de Référence National des cytopénies auto-immunes de l'enfant (CEREVANCE), CIC 1401 INSERM CICP, University Hospital of Bordeaux, Bordeaux, France.
Background: Childhood autoimmune hemolytic anemia (AIHA) is a rare and severe disease characterized by hemolysis and positive direct antiglobulin test (DAT). Few epidemiologic indicators are available for the pediatric population. The objective of our study was to reliably estimate the number of AIHA cases in the French Aquitaine region and the incidence of AIHA in patients under 18 years old.
View Article and Find Full Text PDFAm J Hematol
May 2017
Pediatric Hematology Unit, University Hospital of Angers, Angers, France.
Haematologica
May 2011
Pediatric Hematology Unit, Centre de Référence National des Cytopénies Auto-immunes de l'Enfant (CEREVANCE) Hôpital des Enfants, Hôpital Pellegrin, CHU Bordeaux, Place Amelie Raba Leon, 33 000 Bordeaux, France.
Background: Autoimmune hemolytic anemia is a rare condition in children. Little is known about its initial presentation and the subsequent progression of the disease.
Design And Methods: Since 2004, a national observational study has been aiming to thoroughly describe cases and identify prognostic factors.